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Isolation of induced pluripotent stem cells (iPSCs) from fully differentiated somatic cells has revolutionized existing 
concepts of cell differentiation and stem cells. Importantly, iPSCs generated from somatic cells of patients can be 
used to model different types of human diseases. They may also serve as autologous cell sources that can be used 
in transplantation therapy. In this study, we investigated the neuronal properties of an iPSC line that is derived from 
human neonatal foreskin fibroblasts (FS-1). We initially examined the morphology and marker expression of FS-1 
cells at undifferentiated stage. We then spontaneously differentiated FS-1 cells in suspension culture and examined 
the expression of markers representing three germ layers. We finally differentiated FS-1 cells into neuronal lineages 
by co-culturing them with PA6 stromal cells, and found that, under the conditions we used, they have a tendency 
to differentiate into more forebrain-type neurons, suggesting that FS-1 iPSC-derived neural cells will be useful to be 
used in cell therapy of stroke or Huntington’s disease, among others. Taken together, FS-1 cells derived from human 
neonatal fibroblasts exhibit very similar properties with human ES cells, and can provide useful sources for cell therapy 
and various other applications.
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Introduction 
  Reprogramming of fully differentiated human somatic 
cells into the pluripotent cell state using defined four tran-
scription factors (Oct4, Sox2, c-Myc and Klf4) has com-
pletely changed our existing concept of hierarchical organ-
ization of cell lineage and/or fate determination (1). 
Moreover, this would allow the generation of patient-spe-
cific pluripotent cell lines that can provide immune re-
jection-free autologous sources for novel cell therapies, as 
well as patient-derived, customized materials for disease 
modeling and drug screening (2). Over the past six years 
since the original discovery of iPSCs by Yamanaka and 
colleagues (1), there has been a great expansion of tech-
nologies to establish iPSC lines using more safe and effi-
cient methods (3). 
  In 2007, Thomson group in Wisconsin established mul-
tiple iPSC lines using lentiviral systems overexpressing 
Oct4, Sox2, Nanog and Lin28 (4), without using c-Myc, 
which is known to cause death and differentiation of hu-
man ES cells (5). Interestingly, in this study, they used 
newborn foreskin fibroblasts, in addition to IMR90 fetal 
fibroblasts, for the generation of iPSCs. While fetal fibro-
blasts are derived from aborted human fetuses, newborn 
foreskin is easy to obtain; otherwise, it will be discarded 
after circumcision at birth. Since foreskin can provide 
non-invasive cell sources for iPSC generation and its cell 
age is very young, it will be likely that the resulting iPSCs 
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Table 2. Real-time qPCR primers used in this study
Gene name Forward (F) and reverse (R) primer sequences
Product size 
(bp)
Annealing 
temp. (℃)
No.
cycles
GenBank
accession no.
GATA4
Sox17
Brachyury
Nkx2.5
U6
F: 5’-CTGCTGTCTGTCTGCTCCTC-3’
R: 5’-TGTGTTGTGTTTGTTTGCTTCG-3’
F: 5’-TGTTCAGAGATTTGTTTCCCATAG-3’
R: 5’-ACACACCCAGGACAACATTTC-3’
F: 5’-CCAGTGGCAGTCTCAGGTTAAG-3’
R: 5’-GCAGGTGTGAGCAAGGGATG-3’
F: 5’-CGGTTGGAACTGGGACTGAG-3’
R: 5’-CGACGGCGAGATAGCAAAGG-3’
F: 5'-CTCGCTTCGGCAGCACA-3'
R: 5'-AACGCTTCACCTAATTTGCGT-3'
150
141
116
102
 94
59
59
59
59
59
40
40
40
40
30
NM_002052.3
NM_022454.3
NM_003181.2
NM_004387.3
NR_004394
Table 1. RT-PCR primers used in this study
Gene name Forward (F) and reverse (R) primer sequences
Product size 
(bp)
Annealing 
temp. (℃)
No.
cycles
GenBank
accession no.
Oct4
Nanog
Nestin
Beta III tubulin
Bf-1
En-1
Darpp-32
Calbindin
GFAP
GAPDH
F: 5'-CTGAAGCAGAAGAGGATCAC-3'
R: 5'-GACCACATCCTTCTCGAGCC-3'
F: 5'-TTCTTGACCGGGACCTTGTC-3'
R: 5'-GCTTGCCTTGCTTTGAAGCA-3'
F: 5'-TCCAGAAACTCAAGCACCA-3'
R: 5'-AAATTCTCCAGGTTCCATGC-3'
F: 5'-ATGAGGGAGATCGTGCACAT-3'
R: 5'-GCCCCTGAGCGGACACTGT-3'
F: 5'-CTCAGAACTCGCTGGGCAAC-3'
R: 5'-CGTGGGGGAAAAAGTAACTGG-3'
F: 5'-CTAGCCAAACCGCTTACGAC-3'
R: 5'-GCAGAACAGACAGACCGACA-3'
F: 5'-CCTGAAGGTCATCAGGCAGT-3'
R: 5'-GGTCTTCCACTTGGTCCTCA-3'
F: 5'-GCAAACAAGACTGTTGATGACAC-3'
R: 5'-AAGAGCAAGATCCGTTCGGTAC-3'
F: 5'-GCAGAGATGATGGAGCTCAATGACC-3'
R: 5'-GTTTCATCCTGGAGCTTCTGCCTCA-3'
F: 5'-GTCATACCAGGAAATGAGCT-3'
R: 5'-TGACCACAGTCCATGCCATC-3'
366
256
183
239
225
358
131
363
266
422
60
60
59
59
59
59
50
58
59
60
30
30
30
30
30
30
30
30
30
30
NM_002701.4
NM_024865
NM_006617
BC000748.2
NM_005249
NM_001426.3
AF464196.1
NM_004929.2
BC041765.1
BC083511.1
would have more proliferative activity and differentiation 
potentials, compared with other iPSCs generated from 
aged skin fibroblasts.
  In their original paper, they established four different 
types of iPSCs from foreskin fibroblasts (FS-1, FS-2, FS-3 
and FS-4) and reported the initial characterization results 
(4). However, they didn’t report the detailed analysis on 
the marker expression and differentiation potentials of 
FS-iPSC lines. On the other hand, since FS-iPSC lines 
were generated by lentiviral integration, it is less likely 
that they can be used for therapeutic purposes. Neverthe-
less, considering the practical usefulness of sample collec-
tion and the expected developmental potentials, we de-
cided to focus on FS-1 line for our initial analysis. In this 
study, we initially examined the morphology and marker 
expression of FS-1 cells at undifferentiated stage, and then 
examined their differentiation potentials in suspension 
culture. Finally, we differentiated FS-1 cells into neuronal 
lineages and their properties. Our results indicate that 
FS-1 cells exhibit very similar properties with human ES 
cells and can serve as useful sources for cell therapy and 
various other applications.
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Fig. 1. Morphology and marker expression of FS-1 cells at un-
differentiated stage. (A) A colony showing undifferentiated FS-1 
cells. Immunocytochemical staining showing the expression of 
OCT4 (B), (C) SSEA-4 and (D) TRA-1-81. (E) Semi-quantitative 
RT-PCR showing high levels of Oct4 and Nanog mRNA expression.
Scale bar: 100 μm.
Materials and Methods
Culture and neuronal differentiation of FS-1 hiPSC 
  We cultured and maintained human iPS (Foreskin)-1 
(briefly called FS-1 thereafter; obtained from WiCell, 
Wisconsin, USA) according to the method described pre-
viously (4). FS-1 line was originally established under 
feeder-free condition, but we changed the culture con-
dition so that the cells were maintained in the presence 
of embryonic fibroblasts, which provided more stable cul-
ture conditions. As controls, H9 human ES cells (obtained 
from WiCell) and two human iPSC lines (551-8 and F5), 
which were generated by retroviral integration of Oct4, 
Sox2, c-Myc and Klf-4 (6-8), were used. Neuronal differ-
entiation of iPSCs was induced by co-culturing the cells 
with PA6 stromal cells (obtained from RIKEN Cell Bank) 
as described previously (9). Using 5-stage differentiation 
protocol, we differentiated FS-1 cells into mature neurons 
(7, 8). To do this, we plated neurospheres directly onto 
PLO/FN-coated dishes in DM medium supplemented 
with 20 ng/ml brain-derived neurotrophic factor (BDNF, 
R&D Systems) in the absence of bFGF. 
Immunocytochemical analysis
  To analyze the marker expression of cells from various 
stages, we carried out immunocytochemical analyses using 
the following primary antibodies: OCT4 (1:250, Santa 
Cruz), SSEA-4 (1:100, Developmental Studies Hybridoma 
Bank), TRA-1-81 (1:250, Chemicon), type III β-tubulin 
(Tuj1) (1:500, Chemicon), Myogenin (1:200, Developmen-
tal Studies Hybridoma Bank), SOX17 (1:200, Santa Cruz), 
OTX2 (1:500, Chemicon), MAP2 (1:200, Chemicon), 
NeuN (1:500, Chemicon), Gamma-aminobutyric acid 
(GABA) (1:5,000, Sigma), and TH (1:1,000, Pel-Freez). 
Secondary antibodies used were goat anti-mouse IgG-con-
jugated Alexa-555 (1:200, Molecular Probes), goat an-
ti-rabbit IgG-conjugated Alexa-488 (1:200, Molecular 
Probes) and goat anti-mouse IgM-conjugated Alexa-555 
(1:200, Molecular Probes). DAPI was used to counter-stain 
the cells. Staining patterns were examined and photo-
graphed using a confocal laser-scanning microscope imag-
ing system (LSM510, Carl Zeiss Inc.). 
RNA isolation and reverse transcription polymerase 
chain reaction (RT-PCR) analysis
  We isolated total RNA from cells using Trizol RNA ex-
traction method (Gibco). cDNA was synthesized using 
M-MLV reverse transcriptase (Promega) at 42oC for 1 hr. 
PCR amplification was performed using Taq polymerase ac-
cording to the manufacturer's instructions (Intron, Korea). 
Primer sequences, number of cycles, annealing temperatures 
for semi-quantitative RT-PCR and real-time qPCR are de-
scribed in Table 1 and Table 2, respectively. The house-
keeping genes, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or U6 were used as internal loading controls. 
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Fig. 2. Morphology and marker expression of FS-1 cells after spontaneous differentiation. (A) Formation of embryoid bodies (EBs) at 3, 
8 and 13 days (D3, D8 and D13, respectively) in suspension culture. (B) Immunocytochemical staining showing germ layer-specific markers:
SOX17 (endoderm), Tuj1 (ectoderm) and Myogenin (mesoderm). (C) Real-time qPCR results showing expression of markers for endoderm
(GATA4 and Sox17), mesoderm (Brachyury and Nkx2.5) and ectoderm (βIII Tub [Tuj1] and Nestin). (D) Relative expression of each marker
in FS-1, compared with human ES cells (H9) and two different iPSC lines (551-8 and F5). Expression levels in H9 were set as “1.” Scale 
bar: 50 μm.
Results
Morphology and marker expression of FS-1 cells at 
undifferentiated stage and after spontaneous 
differentiation
  As shown in Fig. 1, we found that morphological char-
acteristics and marker expression patterns of FS-1 cells at 
undifferentiated stage were very similar to those of other 
pluripotent stem cells, including human ES cells (H9, da-
ta not shown) and two other human iPSC lines (551-8 and 
F5, data not shown). Since the original report didn’t pro-
vide these information (4), the current study adds a new 
information on FS-1 cells at undifferentiated stage. While 
the morphology and marker expression in FS-1 cells are 
very similar to those in H9 human ES cells, there is a 
slight difference in the methylation status of Oct4 pro-
moter (4), implying that their epigenetic status are not en-
tirely identical. 
  We also examined the differentiation potential of FS-1 
cells after spontaneous differentiation in suspension 
culture. As shown in Fig. 2, FS-1 cells form embryoid bod-
ies (EBs) (Fig. 2A) and express markers for endoderm 
(SOX17), ectoderm (Tuj1) and mesoderm (Myogenin) 
(Fig. 2B). Real-time qPCR analysis further revealed that 
they express mRNAs for endoderm (GATA4 and Sox17), 
mesoderm (brachyury and Nkx2.5) and ectoderm (type III 
β-tubulin and Nestin) (Fig. 2C). However, comparative 
analysis of each mRNA expression shows some differences 
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Fig. 3. Expression of neuronal markers of FS-1 cells at differentiated
neuronal stage. (A) Semi-quantitative RT-PCR showing expression 
of markers for early neuron (βIII Tub, type III β-tubulin), mature
neuron (Map2), forebrain (Bf-1), mid/hindbrain (En-1), dop-
aminergic neuron (TH), medium spiny neuron (Darpp-32) and stria-
tal neurons (Calbindin). (B) Immunocytochemical staining showing
the expression of mature neurons (NeuN and MAP2), fore-
brain/midbrain (OTX2), early neurons (Tuj1), dopaminergic neu-
rons (TH) and GABAergic neurons (GABA). Scale bar: 50 μm.
in each cell line (Fig. 2D). Interestingly, we observed that 
FS-1 cells are more inclined to differentiate into ecto-
dermal lineage, judged by relatively high expression of 
Tuj1 and Nestin (Fig. 2D). Taken together, these results 
indicate that, although gross morphology and im-
munocytochemical marker expression in FS-1 cells are 
very similar to other pluripotent stem cells, their detailed 
expression levels for specific markers are quite different.
Neuronal differentiation of FS-1 cells
  We have recently shown that our 5-stage differentiation 
protocol is efficient to generate mature neurons (7, 8). 
Using this protocol, we first co-cultured undifferentiated 
FS-1 cells (Stage 1) with PA6 stromal cells (Stage 2) and 
isolated neural rosettes (Stage 3). We then induced neuro-
sphere formation in suspension culture (Stage 4). After-
wards, we further differentiated the cells into mature neu-
rons (MN) (Stage 5-MN). Although it is well known that 
PA6 co-culture method drives the fate of neuronal differ-
entiation into more midbrain-type neurons (9), we found 
that isolation of neuroepithelial cell types at early stage, 
and treatment with BDNF (brain-derived neurotrophic 
factor) renders the nature of neuronal populations to be 
maintained as forebrain-type or GABAergic neurons (8). 
Importantly, with our differentiation protocol we effi-
ciently generated early and mature neurons (i.e., type III 
β-tubulin and Map2). Semi-quantitative RT-PCR results 
showed that the neuronal cells derived from FS-1 cells ex-
press high levels of forebrain (i.e., Bf-1), striatal (i.e., 
Calbindin) and MSN (i.e., Darpp-32) markers (Fig. 3A). 
There are some neurons expressing a marker for 
mid/hindbrain (i.e., En-1). However, expression of mark-
ers for dopaminergic neurons (i.e., TH) or glial cells (i.e., 
GFAP, data not shown) were either very low or absent. 
Immunocytochemical staining further confirmed that 
markers for mature neurons (i.e., NeuN and MAP2) and 
early neurons (i.e., Tuj1) are highly expressed, whereas 
TH-positive dopaminergic neurons are detected only at 
low levels. Expression of markers for fore/midbrain (i.e., 
OTX2) and GABAergic neurons (i.e., GABA) are fre-
quently detectable. Taken together, these results indicate 
that, under the conditions we used, FS-1 cells have a ten-
dency to differentiate into more forebrain-type neurons, 
suggesting that FS-1 iPSC-derived neural cells will be use-
ful to be used in cell therapy of stroke or Huntington’s 
disease, among others. 
Discussion
  In this study, we have extensively analyzed the mor-
phology and marker expression of FS-1 cells at un-
differentiated, after spontaneous differentiation and at dif-
ferentiated neuronal stages. Although the gross morphol-
ogy and immunocytochemical marker expression patterns 
of FS-1 cells are very similar to those of human ES cells 
(H9) and other two different human iPSC lines (551-8 and 
F5), their detailed gene expression patterns and/or levels 
are shown to be somewhat different. Nevertheless, from 
this study and the original report, it is evident that FS-1 
cells meet the general criteria of human pluripotent stem 
cells. Moreover, since foreskin can provide non-invasive 
cell sources for iPSC generation and its cell age is very 
young, it has strong advantages over aged skin fibroblasts 
in many respects. However, even in this case, it will be 
essential to generate iPSC using non-integrating methods, 
such as episomal system (10), from foreskin fibroblasts un-
der good manufacturing protocol (GMP) conditions in or-
der to be used for therapeutic purposes. More recently, 
several groups have published elegant methods to convert 
fibroblasts into neurons directly (iN cells) (11, 12), so it 
will be interesting to apply these technologies to make 
neurons directly from foreskin fibroblasts in the future. 
Taken together, our results indicate that FS-1 cells derived 
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from human neonatal fibroblasts exhibit very similar 
properties with human ES cells, and can provide useful 
sources for cell therapy and various other applications, in-
cluding drug screening.
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